- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00065468
Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC)
September 24, 2012 updated by: Pfizer
A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.
The primary objective of this study is efficacy.
The primary efficacy endpoint of this study is a comparison of the overall survival of subjects treated with CCI-779 [Temsirolimus], administered intravenously [IV] once weekly and the combination of CCI-779, administered IV once weekly with Interferon Alfa [IFN alfa] subcutaneously [SC] three times per week [TIW], compared with the overall survival of subjects treated with IFN alfa (SC TIW) alone, in poor-prognosis subjects with advanced RCC.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
626
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
- Pfizer Investigational Site
-
-
-
-
-
Buenos Aires, Argentina, C1426ANZ
- Pfizer Investigational Site
-
Cordoba, Argentina, 5000
- Pfizer Investigational Site
-
Mendoza, Argentina
- Pfizer Investigational Site
-
Quilmes, Argentina
- Pfizer Investigational Site
-
-
Aires
-
Buenos, Aires, Argentina
- Pfizer Investigational Site
-
-
Tucuman
-
San Miguel de Tucuman, Tucuman, Argentina, 4000
- Pfizer Investigational Site
-
-
-
-
New South Wales
-
Kogarah, New South Wales, Australia, 2217
- Pfizer Investigational Site
-
Newcastle, New South Wales, Australia
- Pfizer Investigational Site
-
Westmead, New South Wales, Australia, 2145
- Pfizer Investigational Site
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Pfizer Investigational Site
-
-
Victoria
-
Footscray, Victoria, Australia, 3012
- Pfizer Investigational Site
-
Heidelberg, Victoria, Australia, 3084
- Pfizer Investigational Site
-
Melbourne, Victoria, Australia, 3050
- Pfizer Investigational Site
-
-
-
-
-
Hamilton, Ontario, Canada, L8N 4A6
- Pfizer Investigational Site
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Pfizer Investigational Site
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 5L3
- Pfizer Investigational Site
-
Vancouver, British Columbia, Canada, V5Z 3J5
- Pfizer Investigational Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0C9
- Pfizer Investigational Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- Pfizer Investigational Site
-
-
Ontario
-
London, Ontario, Canada, N6A 4L5
- Pfizer Investigational Site
-
Newmarket, Ontario, Canada, L3Y 2P9
- Pfizer Investigational Site
-
Ottawa, Ontario, Canada, K1H 8L6
- Pfizer Investigational Site
-
Toronto, Ontario, Canada, M4N 3M5
- Pfizer Investigational Site
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Pfizer Investigational Site
-
Montreal, Quebec, Canada, H3T 1E2
- Pfizer Investigational Site
-
Montreal, Quebec, Canada, H2X 3J4
- Pfizer Investigational Site
-
Montreal, Quebec, Canada, H2L 4M1
- Pfizer Investigational Site
-
Quebec City, Quebec, Canada, G1R 2J6
- Pfizer Investigational Site
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Pfizer Investigational Site
-
-
-
-
-
Brno, Czech Republic, 656 53
- Pfizer Investigational Site
-
Prague 5, Czech Republic, 150 00
- Pfizer Investigational Site
-
-
-
-
Novi Sad
-
Sremska Kamenica, Novi Sad, Former Serbia and Montenegro, 21204
- Pfizer Investigational Site
-
-
-
-
NRW
-
Bonn, NRW, Germany, 53105
- Pfizer Investigational Site
-
Essen, NRW, Germany, 45122
- Pfizer Investigational Site
-
-
RP
-
Mainz, RP, Germany, D-55101
- Pfizer Investigational Site
-
-
-
-
-
Patra, Greece
- Pfizer Investigational Site
-
-
Creete
-
Heraklion, Creete, Greece
- Pfizer Investigational Site
-
-
-
-
-
Budapest, Hungary, H-1122
- Pfizer Investigational Site
-
-
-
-
-
Foggia, Italy, 71100
- Pfizer Investigational Site
-
Milano, Italy, 20132
- Pfizer Investigational Site
-
-
RM
-
Roma, RM, Italy, 00144
- Pfizer Investigational Site
-
-
-
-
-
Daugavpils, Latvia
- Pfizer Investigational Site
-
Riga, Latvia, 1079
- Pfizer Investigational Site
-
Riga, Latvia, 1002
- Pfizer Investigational Site
-
-
-
-
-
Vilnius, Lithuania, 2021
- Pfizer Investigational Site
-
-
-
-
-
Leon Guanajuato, Mexico, 37000
- Pfizer Investigational Site
-
-
Nuevo Leon
-
Monterrey, Nuevo Leon, Mexico, 64000
- Pfizer Investigational Site
-
-
-
-
-
Amsterdam, Netherlands, 1105 AZ
- Pfizer Investigational Site
-
Enschede, Netherlands, 7511 JX
- Pfizer Investigational Site
-
-
GA
-
Nijmegen, GA, Netherlands, 6525
- Pfizer Investigational Site
-
-
-
-
-
Bytom, Poland, 41-902
- Pfizer Investigational Site
-
Lodz, Poland, 93-509
- Pfizer Investigational Site
-
Lublin, Poland, 20-090
- Pfizer Investigational Site
-
Olsztyn, Poland, 10-228
- Pfizer Investigational Site
-
Opole, Poland, 45-060
- Pfizer Investigational Site
-
Poznan, Poland, 61-878
- Pfizer Investigational Site
-
Siedlce, Poland, 08-110
- Pfizer Investigational Site
-
Warszawa, Poland, 02-781
- Pfizer Investigational Site
-
Warszawa, Poland, 00-909
- Pfizer Investigational Site
-
-
-
-
-
Barnaul, Russian Federation, 656052
- Pfizer Investigational Site
-
Kemerovo, Russian Federation, 650003
- Pfizer Investigational Site
-
Moscow, Russian Federation, 115478
- Pfizer Investigational Site
-
Moscow, Russian Federation, 143423
- Pfizer Investigational Site
-
Moscow, Russian Federation, 125284
- Pfizer Investigational Site
-
Moscow, Russian Federation, 121356
- Pfizer Investigational Site
-
Obninsk, Russian Federation, 249036
- Pfizer Investigational Site
-
Saint Petersburg, Russian Federation, 188663
- Pfizer Investigational Site
-
Saint Petersburg, Russian Federation, 194354
- Pfizer Investigational Site
-
Saint Petersburg, Russian Federation, 197758
- Pfizer Investigational Site
-
Saint Petersburg, Russian Federation
- Pfizer Investigational Site
-
St Petersburg, Russian Federation, 197758
- Pfizer Investigational Site
-
Ufa, Russian Federation, 450005
- Pfizer Investigational Site
-
Ufa, Russian Federation
- Pfizer Investigational Site
-
-
-
-
-
Belgrade, Serbia, 11000
- Pfizer Investigational Site
-
-
-
-
-
Banska Bystrica, Slovakia, 974 01
- Pfizer Investigational Site
-
Bratislava, Slovakia, 833 10
- Pfizer Investigational Site
-
Martin, Slovakia, 03659
- Pfizer Investigational Site
-
Zlina, Slovakia, 012 07
- Pfizer Investigational Site
-
-
-
-
-
Cape Town, South Africa, 7505
- Pfizer Investigational Site
-
Gauteng, South Africa
- Pfizer Investigational Site
-
-
Eastern Cape
-
Port Elizabeth, Eastern Cape, South Africa, 6006
- Pfizer Investigational Site
-
-
Gauteng
-
Johannesburg, Gauteng, South Africa, 2197
- Pfizer Investigational Site
-
-
-
-
-
Barcelona, Spain, 08025
- Pfizer Investigational Site
-
Madrid, Spain, 28040
- Pfizer Investigational Site
-
-
Asturias
-
Oviedo, Asturias, Spain, 33006
- Pfizer Investigational Site
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Pfizer Investigational Site
-
-
-
-
-
Göteborg, Sweden, 41345
- Pfizer Investigational Site
-
Stockholm, Sweden, 171 76
- Pfizer Investigational Site
-
Uppsala, Sweden, 751 85
- Pfizer Investigational Site
-
-
-
-
-
Taichung, Taiwan
- Pfizer Investigational Site
-
Taipei, Taiwan, 104
- Pfizer Investigational Site
-
Taoyuan, Taiwan, 333
- Pfizer Investigational Site
-
-
ROC
-
Taipei, ROC, Taiwan, 112
- Pfizer Investigational Site
-
-
-
-
-
Istanbul, Turkey
- Pfizer Investigational Site
-
Izmir, Turkey, 35100
- Pfizer Investigational Site
-
-
-
-
-
Dnietropetrovsk, Ukraine
- Pfizer Investigational Site
-
Donetsk, Ukraine, 83 092
- Pfizer Investigational Site
-
Kharkov, Ukraine, 61 037
- Pfizer Investigational Site
-
Kiev, Ukraine, 03 142
- Pfizer Investigational Site
-
Lviv, Ukraine, 79031
- Pfizer Investigational Site
-
Zaporozhye, Ukraine, 69103
- Pfizer Investigational Site
-
-
-
-
-
Nottingham, United Kingdom, NG5 1PB
- Pfizer Investigational Site
-
-
Lancashire
-
Manchester, Lancashire, United Kingdom, M20 4BX
- Pfizer Investigational Site
-
-
Strathclyde
-
Glasgow, Strathclyde, United Kingdom, G11 6NT
- Pfizer Investigational Site
-
-
Surrey
-
Sutton, Surrey, United Kingdom, SM2 5PT
- Pfizer Investigational Site
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Pfizer Investigational Site
-
-
California
-
La Verne, California, United States, 91750
- Pfizer Investigational Site
-
Los Angeles, California, United States, 90024-2828
- Pfizer Investigational Site
-
San Diego, California, United States, 92123
- Pfizer Investigational Site
-
San Francisco, California, United States, 94115
- Pfizer Investigational Site
-
-
Connecticut
-
Waterbury, Connecticut, United States, 06708
- Pfizer Investigational Site
-
-
Florida
-
Boca Raton, Florida, United States, 33428
- Pfizer Investigational Site
-
Miami, Florida, United States, 33136
- Pfizer Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States, 60612-3824
- Pfizer Investigational Site
-
Urbana, Illinois, United States, 61801
- Pfizer Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46303
- Pfizer Investigational Site
-
South Bend, Indiana, United States, 46601
- Pfizer Investigational Site
-
Terre Haute, Indiana, United States, 47802
- Pfizer Investigational Site
-
-
Kansas
-
Kansas City, Kansas, United States, 66160-7136
- Pfizer Investigational Site
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Pfizer Investigational Site
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Pfizer Investigational Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21231-1000
- Pfizer Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Pfizer Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-0942
- Pfizer Investigational Site
-
Detroit, Michigan, United States, 48202
- Pfizer Investigational Site
-
-
Missouri
-
Kansas City, Missouri, United States, 64131
- Pfizer Investigational Site
-
St. Louis, Missouri, United States, 63110
- Pfizer Investigational Site
-
-
Montana
-
Billings, Montana, United States, 59101
- Pfizer Investigational Site
-
Great Falls, Montana, United States, 59405
- Pfizer Investigational Site
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03766
- Pfizer Investigational Site
-
-
New Jersey
-
East Orange, New Jersey, United States, 07018
- Pfizer Investigational Site
-
Morristown, New Jersey, United States, 07960
- Pfizer Investigational Site
-
-
New York
-
Bronx, New York, United States, 10466
- Pfizer Investigational Site
-
New York, New York, United States, 10021
- Pfizer Investigational Site
-
Rochester, New York, United States, 14642
- Pfizer Investigational Site
-
Valhalla, New York, United States, 10595
- Pfizer Investigational Site
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Pfizer Investigational Site
-
Hickory, North Carolina, United States, 28602
- Pfizer Investigational Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Pfizer Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Pfizer Investigational Site
-
-
Oregon
-
Portland, Oregon, United States, 97213-2933
- Pfizer Investigational Site
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033-0850
- Pfizer Investigational Site
-
Philadelphia, Pennsylvania, United States, 19111
- Pfizer Investigational Site
-
Pittsburgh, Pennsylvania, United States, 15213
- Pfizer Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, United States, 29414
- Pfizer Investigational Site
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- Pfizer Investigational Site
-
Memphis, Tennessee, United States, 38120
- Pfizer Investigational Site
-
Nashville, Tennessee, United States, 37232-6310
- Pfizer Investigational Site
-
-
Texas
-
Houston, Texas, United States, 77030
- Pfizer Investigational Site
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Pfizer Investigational Site
-
-
Virginia
-
Richmond, Virginia, United States, 23249
- Pfizer Investigational Site
-
-
Washington
-
Seattle, Washington, United States, 98109-1023
- Pfizer Investigational Site
-
Seattle, Washington, United States, 98101
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- This study will be conducted in subjects with histologically confirmed, advanced (stage IV or recurrent disease) RCC who have not received prior systemic therapy for their disease,
Exclusion Criteria:
- Subjects with central nervous system (CNS) metastases
- Prior anticancer therapy for RCC
- Prior investigational therapy/agents within 4 weeks of randomization
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: A
|
Interferon alfa (Roferon) 3 MU given Sub Cutaneously three time /week for the first week, 9 MU given Sub Cutaneously three time /week for the second week, 18 MU given Sub Cutaneously three time /week thereafter.
|
Experimental: B
|
25 mg of CCI-779 given Intra Venously once per week
|
Experimental: C
|
15 mg of CCI-779 given Intra Venously once per week; 6 MU of IFN alfa (Roferon) given Sub Cutaneously three time /week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: Baseline up to Month 80
|
Overall survival is the duration from randomization to death.
For participants who are alive, overall survival is censored at the last contact.
|
Baseline up to Month 80
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: Baseline, monthly until tumor progression or death (up to Month 80)
|
PFS based on Independent Central Review Assessment.
The period from randomization until disease progression, death or date of last contact.
|
Baseline, monthly until tumor progression or death (up to Month 80)
|
Percentage of Participants With Objective Response
Time Frame: Baseline, every 2 months until tumor progression or death (up to Month 80)
|
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST).
CR was the disappearance of all target lesions and non target lesions.
PR was at least a 30 percent (%) decrease in sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
|
Baseline, every 2 months until tumor progression or death (up to Month 80)
|
Percentage of Participants With Clinical Benefit
Time Frame: Baseline, every 2 months until tumor progression or death (up to Month 80)
|
Clinical benefit: confirmed CR or PR or had stable disease (SD) lasting at least 24 weeks.
CR was the disappearance of all target lesions and non target lesions.
PR was at least a 30% decrease in sum of the LD of target lesions, taking as reference the baseline sum LD.
SD was having neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
|
Baseline, every 2 months until tumor progression or death (up to Month 80)
|
Duration of Response (DR)
Time Frame: Baseline, every month until tumor progression or death (up to Month 80)
|
DR: Time from first documentation of objective tumor response to first date that recurrence or progressive disease (PD) was objectively documented, taking as a reference for PD, the smallest sum LD recorded since randomization.
|
Baseline, every month until tumor progression or death (up to Month 80)
|
Time to Treatment Failure (TTF)
Time Frame: Baseline, every month until tumor progression or death (up to Month 80)
|
TTF is defined as the time from the date of randomization to the date of PD or death, withdrawal from treatment due to an adverse event (AE), withdrawal of voluntary consent, or lost to follow-up, whichever occurred first, censored at the date of the conclusion of treatment phase.
|
Baseline, every month until tumor progression or death (up to Month 80)
|
Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST)
Time Frame: Baseline to Month 80
|
The Q-Twist is not a score calculated for each participant but is defined only on a by treatment group basis.
For each treatment group, it is the weighted sum of the mean durations of the health states Tox, Twist, and Relapse.
Tox is defined as time with severe toxicity related to treatment; Twist: time without symptoms or toxic side effects; and Relapse: time after relapse/progression.
The mean duration of each health state is calculated based on the area under the Kaplan Meier curve pertaining to that health state.
There is no direct method for calculating the "dispersion" of Q-Twist, and it is typically done using bootstrap method for purposes of inference (see, e.g., Glasziou PP, Simes RJ, Gelber RD.
Quality adjusted survival analysis.
Stat Med 1990; 9: 1259-76).
In practice, as apparently in the case with this study, the intermediate values resulting from the bootstrap exercise were not displayed.
|
Baseline to Month 80
|
European Quality of Life Health Questionnaire (EQ-5D) - Index Score
Time Frame: Baseline
|
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value.
EQ-5D index measured 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Range of EQ-5D index score = -0.594 to 1 where higher scores indicated a better health state.
|
Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21.
- Grunwald V, Lin X, Kalanovic D, Simantov R. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. Eur Urol. 2016 Dec;70(6):1006-1015. doi: 10.1016/j.eururo.2016.05.010. Epub 2016 May 26.
- Grunwald V, McKay RR, Krajewski KM, Kalanovic D, Lin X, Perkins JJ, Simantov R, Choueiri TK. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol. 2015 May;67(5):952-8. doi: 10.1016/j.eururo.2014.12.036. Epub 2015 Jan 7.
- Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007 May 31;356(22):2271-81. doi: 10.1056/NEJMoa066838.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2003
Primary Completion (Actual)
June 1, 2006
Study Completion (Actual)
March 1, 2011
Study Registration Dates
First Submitted
July 24, 2003
First Submitted That Met QC Criteria
July 24, 2003
First Posted (Estimate)
July 25, 2003
Study Record Updates
Last Update Posted (Estimate)
October 25, 2012
Last Update Submitted That Met QC Criteria
September 24, 2012
Last Verified
September 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Carcinoma
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Interferons
- Interferon-alpha
- Sirolimus
Other Study ID Numbers
- 3066K1-304
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Neoplasms
-
Philips HealthcareWithdrawnKidney TumorsUnited States
-
St. Petersburg State Pavlov Medical UniversitySaint Petersburg State University, RussiaCompleted
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedKidney TumorUnited States
-
Tianjin Medical University Second HospitalRecruiting
-
Thomas MuellerUnknownKidney Neoplasms | Adult Polycystic Kidney Disease | Kidney DysfunctionSwitzerland
-
Tianjin Medical University Second HospitalRecruiting
-
Intuitive SurgicalCompleted
-
Yale UniversityCompleted
-
Stanford UniversityNational Cancer Institute (NCI)WithdrawnProstate Cancer | Bladder Cancer | Kidney Tumor
-
Association of Urologic Oncology (AUO)IAG-N at German Cancer Association (Deutsche Krebsgesellschaft e. V.)Not yet recruiting
Clinical Trials on Interferon Alfa
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Columbia UniversityMerck Sharp & Dohme LLCWithdrawnEnd Stage Renal Disease | Hepatitis C Infection
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedBreast Cancer | Metastatic CancerUnited States
-
Pusan National University HospitalUnknownChronic Hepatitis BKorea, Republic of
-
National Institute of Allergy and Infectious Diseases...Completed
-
Merck Sharp & Dohme LLCTerminated
-
Merck Sharp & Dohme LLCTerminated
-
National Taiwan University HospitalNational Science Council, TaiwanCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBladder Cancer | Urethral CancerUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)SuspendedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Symptomatic COVID-19 Infection Laboratory-ConfirmedUnited States